Improve movement through brain stimulation
- Trial ID
- NCT06297538
- Official Title
- Targeting the Motor Cortex in Parkinson's Disease by Gamma-transcranial Alternating Current Stimulation: Pathophysiological and Therapeutic Implications
- Goal
- Improve movement through brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Neuromed IRCCS
- Study Type
- INTERVENTIONAL
- Enrollment
- 84 participants
- Conditions
- Parkinson Disease
- Interventions
- gamma transcranial alternating current stimulation (tACS), sham transcranial alternating current stimulation (tACS)
Plain-Language Summary
The goal is to test whether boosting gamma-frequency brain rhythms over the motor cortex can normalize abnormal motor network activity and improve movement in Parkinson's disease. The approach uses gamma transcranial alternating current stimulation, a noninvasive method that applies a very weak, rhythmic electrical current through the scalp to entrain gamma oscillations in the motor cortex, with participants randomized to real or sham tACS so effects can be compared. It is a non-drug, add-on strategy that aims to change cortical excitability and plasticity and could complement levodopa rather than replace it; people taking other drugs that affect brain excitability are excluded. The trial is open to adults 18 and older with Parkinson's, excluding those with severe cognitive or psychiatric issues, Hoehn and Yahr stage above 3, a tremor-dominant phenotype or levodopa-induced dyskinesia, or any contraindication to noninvasive brain stimulation.
Locations
- IRCCS Neuromed, Pozzilli, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying gamma transcranial alternating current stimulation (tACS). The goal is to test whether boosting gamma-frequency brain rhythms over the motor cortex can normalize abnormal motor network activity and improve movement in Parkinson's disease. The approach uses gamma transcranial alternating current stimulation, a noninvasive method that applies a very weak, rhythmic electrical current through the scalp to entrain gamma oscillations in the motor cortex, with participants randomized to real or sham tACS so effects can be compared. It is a non-drug, add-on strategy that aims to change cortical excitability and plasticity and could complement levodopa rather than replace it; people taking other drugs that affect brain excitability are excluded. The trial is open to adults 18 and older with Parkinson's, excluding those with severe cognitive or psychiatric issues, Hoehn and Yahr stage above 3, a tremor-dominant phenotype or levodopa-induced dyskinesia, or any contraindication to noninvasive brain stimulation.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 6 months.